Size | Price | Stock | Qty |
---|---|---|---|
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Fenticonazole is an azole class of antifungal drug used locally as the nitrate form for the treatment of vulvovaginal candidiasis. It is a 14-α demethylase inhibitor and potentially a glucosamine-6-phosphate synthase inhibitor. It is active against a range of organisms including dermatophyte pathogens, Malassezia furfur, and Candida albicans. Application of fenticonazole nitrate 1 g intravaginal ovules on 2 alternate days is a suitable first-line treatment of vulvovaginitis with acceptable broad-spectrum efficacy against the most commonly involved pathogens and with a low rate of early relapse, reserving antibiotics for patients with treatment failure or relapse of infection .
ln Vitro |
Fenticonazole is an azole antifungal medication that is applied topically as a nitrate to treat vaginal candidiasis. Malassezia furfur, Candida albicans, and dermatophyte infections are only a few of the species it is effective against [2].
|
---|---|
References |
|
Additional Infomation |
Fenticonazole nitrate is a racemate comprising equimolar amounts of (R)- and (S)-fenticonazole nitrate. Used for the treatment of vaginal candidiasis. It has a role as an antibacterial drug. It is a racemate, an imidazole antifungal drug and a conazole antifungal drug. It contains a (S)-fenticonazole nitrate and a (R)-fenticonazole nitrate.
|
Molecular Formula |
C24H20CL2N2OS.HNO3
|
|
---|---|---|
Molecular Weight |
518.41
|
|
Exact Mass |
517.062
|
|
Elemental Analysis |
C, 55.61; H, 4.08; Cl, 13.68; N, 8.11; O, 12.34; S, 6.18
|
|
CAS # |
73151-29-8
|
|
Related CAS # |
72479-26-6;73151-29-8 (nitrate);
|
|
PubChem CID |
51754
|
|
Appearance |
White to off-white solid powder
|
|
Density |
1.26g/cm3
|
|
Boiling Point |
637.2ºC at 760 mmHg
|
|
Melting Point |
135-137ºC
|
|
Flash Point |
339.2ºC
|
|
Index of Refraction |
1.632
|
|
LogP |
7.474
|
|
Hydrogen Bond Donor Count |
1
|
|
Hydrogen Bond Acceptor Count |
6
|
|
Rotatable Bond Count |
8
|
|
Heavy Atom Count |
34
|
|
Complexity |
524
|
|
Defined Atom Stereocenter Count |
0
|
|
SMILES |
ClC1C([H])=C(C([H])=C([H])C=1C([H])(C([H])([H])N1C([H])=NC([H])=C1[H])OC([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])SC1C([H])=C([H])C([H])=C([H])C=1[H])Cl.O([H])[N+](=O)[O-]
|
|
InChi Key |
MXQVMHNIUUXDQW-UHFFFAOYSA-O
|
|
InChi Code |
InChI=1S/C24H20Cl2N2OS.NO3/c25-19-8-11-22(23(26)14-19)24(15-28-13-12-27-17-28)29-16-18-6-9-21(10-7-18)30-20-4-2-1-3-5-20;2-1(3)4/h1-14,17,24H,15-16H2;/q;-1/p+1
|
|
Chemical Name |
1-(2-(2,4-dichlorophenyl)-2-((4-(phenylthio)benzyl)oxy)ethyl)-1H-imidazol-3-ium nitrate
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : 100~104 mg/mL (192.90~ 200.61 mM )
Ethanol : ~2 mg/mL |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.82 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.5 mg/mL (4.82 mM) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9290 mL | 9.6449 mL | 19.2898 mL | |
5 mM | 0.3858 mL | 1.9290 mL | 3.8580 mL | |
10 mM | 0.1929 mL | 0.9645 mL | 1.9290 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.